positions available now

Category Archives: Market Access

Relating to Market Access sector of Life Sciences Industry

Commercial Eyes appoints Simon Higgins to head up new Commercialisation Services division

Commercial Eyes Pty. Ltd., one of Australia’s most successful health technology commercialisation companies, is pleased to announce the appointment of Simon Higgins to head up it’s new Commercialisation Services division. Simon joins Commercial Eyes with over 20 years’ experience in … Continue reading

Posted in Commercial Eyes, Commercialisation Services, Market Access, Market Insight, Medical Communications, Medical Services, Regulatory Services | Tagged , , , , | Comments Off on Commercial Eyes appoints Simon Higgins to head up new Commercialisation Services division

PHARMAC prepares to take over the procurement of medical devices

Access to medical devices in New Zealand is changing   The Therapeutic Products Bill will be published shortly, resulting in PHARMAC assuming responsibility for the procurement and funding of medical devices in addition to their current brief of medicines. This … Continue reading

Posted in Life Sciences Industry, Market Access, Medical Device | Tagged , , , , , , | Comments Off on PHARMAC prepares to take over the procurement of medical devices

PHARMAC issues a call for funding applications for medicines for rare disorders

Applications will be accepted until 5pm on the 5th of August 2019 and will be considered by the Rare Disorders Subcommittee at their meeting scheduled for the 24th of September 2019.   Eligibility criteria: The medicine must have been approved … Continue reading

Posted in Life Sciences Industry, Market Access | Tagged , , | Comments Off on PHARMAC issues a call for funding applications for medicines for rare disorders

November 2018 PBAC Meeting Agenda

The November 2018 PBAC Meeting is scheduled to conclude today. Here, the Commercial Eyes Market Access team provides an analysis of the meeting agenda, including Sponsors with multiple submissions and the nature of requested listings by type.     The … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , | Comments Off on November 2018 PBAC Meeting Agenda

PBAC Meeting Outcomes – July 2018

The July 2018 PBAC Meeting Outcomes were published on 17th August 2018. With 64 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including additional analysis conducted on biosimilar and oncology submissions.   … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , , | Comments Off on PBAC Meeting Outcomes – July 2018

Public Submissions to the August 2018 PBAC Special Meeting – Part 2

In the second part of this two-part series (Read Part 1 about here) we bring you further insight into opinions from the public submissions to the August 2018 PBAC Special Meeting. Opinions from the Public Submissions Outcomes of the PBAC’s … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , , , , | Comments Off on Public Submissions to the August 2018 PBAC Special Meeting – Part 2

Public Submissions to the August 2018 PBAC Special Meeting – Part 1

In the first of a two-part series, we provide insights into opinions from 28 public submissions to the August 2018 PBAC Special Meeting held on 17 August 2018 regarding considerations for PD-1 and PD-L1 checkpoint inhibitors for multiple cancer types … Continue reading

Posted in Market Access, PBAC, PBS, Uncategorized | Tagged , , , , | Comments Off on Public Submissions to the August 2018 PBAC Special Meeting – Part 1

PBAC Special Meeting – August 2018

The August 2018 PBAC special meeting is scheduled for 17 August 2018 to consider options for listing PD-1 and PD-L1 checkpoint inhibitors for the treatment of multiple tumours (pan-tumour indications) on the PBS. Here, the Commercial Eyes Market Access team … Continue reading

Posted in Market Access, PBAC | Tagged , , , , , | Comments Off on PBAC Special Meeting – August 2018

Sponsors struggle with Ministerial discretion

The 2017 Medicines Australia Strategic Agreement with the Australian Government extended the existing five-year anniversary statutory price reduction (SPR) of 5% for F1 medicines and introduced new SPRs for drugs that have been listed for ten years and fifteen years … Continue reading

Posted in Life Sciences Industry, Market Access, PBS | Tagged , , , | Comments Off on Sponsors struggle with Ministerial discretion

The long road to PBS listing for Orkambi

Orkambi (lumacaftor and ivacaftor), a treatment for cystic fibrosis (CF), will go before the PBAC for a fourth time at the upcoming July 2018 PBAC meeting. So far, the road to reimbursement has been filled with multiple rejections, a strong … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , , , | Comments Off on The long road to PBS listing for Orkambi
Copyright © 2014 Commercial Eyes